- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism…
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy…